Review of the Therapeutic Advance of Acne Treatment

Acne vulgaris is among the most frequent chronic skin disorders in adolescents, characterized by inflammation of the pilosebaceous unit. The psychological distress due to the disfiguring is the main problem that affects the quality of life for patients suffering from acne. Drugs for the treatment of acne are one of the main contents of drug research on common skin diseases. Acne treatment has remained relatively unaltered over the last years. Still, in conjunction with the increase of bacterial resistance to antibiotics throughout the world, there is a global trend away from antibiotic monotherapy treatment. This review discussed the currently used treatment options and evaluated the issues and evidence supporting their usage for patients with acne, including drug therapy with topical, oral, hormonal therapy, and so on. Drug therapy is the most common method in the clinic. Due to the multifactorial etiology of acne vulgaris, most drugs cannot meet the treatment requirements. Therefore, the screening and development of excellent drugs are one of the key targets for treating acne in the future.

Clinical characteristics and outcomes of psoriasis patients with COVID-19:A retrospective,multicenter cohort study in China

Background:Limited information exists regarding the impact of severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)infection on psoriasis patients.The objective of this study was to identify clinical factors associated with the prognosis of psoriasis following SARS-CoV-2 infection.Methods:A retrospective,multicenter study was conducted between March and May 2023.Univariable and multivariable logistic regression analyses were employed to identify factors associated with coronavirus disease 2019(COVID-19)-related psoriasis outcomes.The study included 2371 psoriasis patients from 12 clinical centers,with 2049 of them having been infected with SARS-CoV-2.Results:Among the infected groups,lower exacerbation rates were observed in individuals treated with biologics compared to those receiving traditional systemic or nonsystemic treatments(22.3%[236/1058]vs.39.8%[92/231]vs.37.5%[140/373],P<0.001).Psoriasis progression with lesions(adjusted odds ratio[OR]=8.197,95%confidence interval[95%CI]=5.685-11.820,compared to no lesions),hypertension(adjusted OR=1.582,95%CI=1.068-2.343),traditional systemic(adjusted OR=1.887,95%CI=1.263-2.818),and nonsystemic treatment(adjusted OR=1.602,95%CI=1.117-2.297)were found to be associated with exacerbation of psoriasis after SARS-CoV-2 infection,but not biologics(adjusted OR=0.931,95%CI=0.680-1.274,compared to no treatment),according to multivariable logistic regression analysis.Conclusions:A reduced risk of psoriasis exacerbation after SARS-CoV-2 infection was observed with biologics compared to traditional systemic and nonsystemic treatments.Significant risk factors for exacerbation after infection were identified as existing psoriatic lesions and hypertension.